The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics PLC , a person familiar with the matter told Reuters.
Amgen struck a deal last year to buy Horizon to strengthen its rare diseases drugs portfolio. The company has said itAmgen said on Monday it wasn't aware of any decision made by the agency. "We will provide any appropriate updates when we have more information," the company said in a statement.
The Democratic Senator said both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon’s Krystexxa, a gout medication.It is unusual for the agency to sue to stop a pharmaceutical deal. In recent years, the agency has usually identified ailments where the merging companies made treatments, and required one of the two medicines to be divested.
Orphan status also means they would likely not be among the drugs for which the U.S. government's Medicare program can negotiate lower drug prices under the Biden Administration's Inflation Reduction Act.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Horizon shares sink on report that FTC will sue to block takeover by AmgenShares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen...
Consulte Mais informação »
'Mars Horizon 2' game is getting a real scientist to help with realismThe team behind the highly anticipated 'Mars Horizon 2' game has recruited a real planetary scientist to ensure the game is as realistic as reasonably practicable.
Consulte Mais informação »
Breakingviews - Vietnam’s Tesla debuts with wrong kind of powerPham Nhat Vuong is arriving in the United States in so-so 2021 style. Vietnam’s richest man is taking his electric-vehicle company, VinFast, public at a punchy valuation through a merger with casino mogul Lawrence Ho’s special-purpose acquisition company. It values the group at $27 billion and secures it a listing in the U.S. where the money-losing entity wants to sell more vehicles. But it needs funding to grow too, and the inflated deal doesn’t help much.
Consulte Mais informação »
Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapySarepta Therapeutics Inc.’s stock soared 30% premarket Monday, after a U.S. Food and Drug Administration panel voted 8-6 in favor of accelerated approval for...
Consulte Mais informação »
Save Time and Money Between Salon Visits With This Root Touch-Up Spray That Has 8,700+ 5-Star Reviews - E! OnlineGood hair days are on the horizon. Fix grown out roots and greys with this game-changing hair product.
Consulte Mais informação »
Sarepta surges after FDA panel backs Duchenne gene therapyShares of Sarepta Therapeutics jumped 25% on Monday as a backing by the U.S. health regulator's advisers increased the certainty of an accelerated approval for the company's gene therapy for a muscle-wasting genetic disorder.
Consulte Mais informação »